1. Home
  2. NLOP vs CHRS Comparison

NLOP vs CHRS Comparison

Compare NLOP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NLOP

Net Lease Office Properties of Beneficial Interest

HOLD

Current Price

$11.58

Market Cap

176.7M

Sector

N/A

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.39

Market Cap

209.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NLOP
CHRS
Founded
N/A
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
176.7M
209.8M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
NLOP
CHRS
Price
$11.58
$1.39
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
175.0K
1.1M
Earning Date
05-19-2026
05-07-2026
Dividend Yield
52.20%
N/A
EPS Growth
N/A
472.00
EPS
1.69
N/A
Revenue
$118,915,000.00
N/A
Revenue This Year
N/A
$73.08
Revenue Next Year
N/A
$30.94
P/E Ratio
$6.93
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.95
$0.81
52 Week High
$34.31
$2.62

Technical Indicators

Market Signals
Indicator
NLOP
CHRS
Relative Strength Index (RSI) 53.97 40.92
Support Level $11.60 $1.39
Resistance Level $12.26 $1.42
Average True Range (ATR) 0.30 0.09
MACD 0.08 -0.01
Stochastic Oscillator 77.51 10.00

Price Performance

Historical Comparison
NLOP
CHRS

About NLOP Net Lease Office Properties of Beneficial Interest

Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns, operates, and finances a diversified portfolio of office properties mainly leased to corporate tenants on a single-tenant, net-lease basis. The company operates as a single operating and reportable segment focused on owning and managing office properties that generate revenue mainly from long-term lease agreements with tenants.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: